Neoplasms, Plasma Cell: all 2,314 studies
Page 15 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- Daratumumab in Combination With ATRACompletedNCT02751255Phase 1/2
- A Diagnostic Screening Trial Seeking AL Amyloidosis Very EarlyCompletedNCT02741999
- Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])CompletedNCT02741544
- To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple MyelomaTerminatedNCT02732925Not applicable
- Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot StudyCompletedNCT02697383Phase 1
- Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaCompletedNCT02697344Phase 1
- Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02692339
- Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple MyelomaNo longer availableNCT02666209
- Study of bb2121 in Multiple MyelomaCompletedNCT02658929Phase 1
- GO-203-2C + Bortezomib For Relapsed Or Refractory MMWithdrawnNCT02658396Phase 1
- Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple MyelomaCompletedNCT02655458Phase 1
- Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsCompletedNCT02649790Phase 1/2
- Multiparametric Imaging in Multiple MyelomaCompletedNCT02646085Phase 1
- Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseCompletedNCT02636010Phase 2
- Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple MyelomaWithdrawnNCT02628704Phase 2
- Multiple Myeloma Minimal Residual DiseaseCompletedNCT02627261
- Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple MyelomaStatus unknownNCT02624440Phase 2
- A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02616640Phase 1
- A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple MyelomaCompletedNCT02609230Phase 1
- A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive DiseaseCompletedNCT02608515
- STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTSCompletedNCT02586038Phase 2
- Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT02579824Phase 1
- UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD CombinationWithdrawnNCT02578121Phase 2
- PDD vs PAD to Treat Initially Diagnosed MMStatus unknownNCT02577783Phase 4
- GEM-CLARIDEX: Ld vs BiRdStatus unknownNCT02575144Phase 3
- Clarithromycin in Multiple Myeloma Induction TherapyTerminatedNCT02573935Phase 2
- Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM PatientsStatus unknownNCT02572596Not applicable
- Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell SupportStatus unknownNCT02572492Phase 2
- HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple MyelomaCompletedNCT02569320Phase 1
- An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple MyelomaNo longer availableNCT02568943
- Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin AmericaCompletedNCT02559583
- Modified Bortezomib-based Combination Therapy for Multiple MyelomaStatus unknownNCT02559154Phase 4
- A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in KoreaCompletedNCT02556905
- Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical PracticeCompletedNCT02555839
- Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple MyelomaActive, not recruitingNCT02542657Phase 1/2
- Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple MyelomaNo longer availableNCT02541643
- Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple MyelomaCompletedNCT02537808
- A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02519452Phase 1
- Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple MyelomaStatus unknownNCT02519114Phase 1/2
- A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple MyelomaCompletedNCT02514668Phase 1
- Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02514382Phase 1
- Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate TransplantationCompletedNCT02513186Phase 1
- Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid MalignanciesStatus unknownNCT02507479Phase 2
- Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple MyelomaCompletedNCT02504359Phase 1
- A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02497378Phase 1
- A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed MyelomaCompletedNCT02495922Phase 3
- Lonquek for Autologous Stem Cell MobilizationStatus unknownNCT02488382Phase 1/2
- Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple MyelomaApproved for marketingNCT02477891
- Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple MyelomaCompletedNCT02474563
- Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma PatientsCompletedNCT02471820Phase 2
- The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain TherapyStatus unknownNCT02467647Phase 1
- Relapse Myeloma; Cyclofosfamide; Bortezomib; MaintenanceCompletedNCT02467010Phase 2
- Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple MyelomaTerminatedNCT02462525Phase 1
- Allogeneic Stem Cell Transplantation for Patients With Multiple MyelomaWithdrawnNCT02447055Early Phase 1
- Non-interventional Study on Salvage Auto in Relapsed MyelomaCompletedNCT02439476
- Exercise in Patients With Multiple MyelomaCompletedNCT02439112Not applicable
- A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)CompletedNCT02431208Phase 1
- Clinical Study of CWP232291 in Relapsed or Refractory Myeloma PatientsCompletedNCT02426723Phase 1
- "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "CompletedNCT02419118Phase 2/3
- Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
- Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT02410694Phase 2
- Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT02406222Phase 2
- Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple MyelomaCompletedNCT02406144Phase 3
- Imageguided Theranostics in Multiple MyelomaCompletedNCT02403102
- A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple MyelomaWithdrawnNCT02402725Phase 2
- ATRA, Celecoxib, and Itraconazole as MaintenanceCompletedNCT02401295Phase 1
- Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple MyelomaTerminatedNCT02400242Phase 1
- Post-authorisation Study of Biological Relapse in Patients With Multiple MyelomaTerminatedNCT02394210
- Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsWithdrawnNCT02389543Phase 1/2
- A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TRStatus unknownNCT02387879
- Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) PatientsCompletedNCT02384083Phase 1/2
- A Study of VLX1570 and Dexamethasone in Myeloma PatientsTerminatedNCT02372240Phase 1/2
- Expanded Access Treatment Protocol CA204-143No longer availableNCT02368301
- CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple MyelomaStatus unknownNCT02362165Phase 3
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Phase 2
- Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple MyelomaActive, not recruitingNCT02315716Phase 2
- Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma PatientsCompletedNCT02308280Phase 2
- B-Cell Hematologic Malignancy Vaccination RegistryWithdrawnNCT02298816
- Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 CarfilzomibTerminatedNCT02294357Phase 2
- Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction ChemotherapyCompletedNCT02288741Phase 3
- Prolonged Protection From Bone Disease in Multiple MyelomaCompletedNCT02286830Phase 4
- SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM PatientsCompletedNCT02283775Phase 1
- Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02278315Phase 1
- Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple MyelomaCompletedNCT02275403Phase 2
- Novel Support Options in Autologous Stem Cell Transplant for Multiple MyelomaCompletedNCT02274519Not applicable
- A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple MyelomaCompletedNCT02268890Phase 4
- Study Evaluating Venetoclax in Subjects With Hematological MalignanciesCompletedNCT02265731Phase 1/2
- Effects of Anticoagulant Preventive Injection in Patients With Blood CancerCompletedNCT02260414Phase 2
- A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple MyelomaCompletedNCT02252263Phase 1
- Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT02248428Phase 3
- Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT02248402Phase 1/2
- A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)CompletedNCT02244125Phase 2
- Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic CancerStatus unknownNCT02240537Phase 1
- Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple MyelomaCompletedNCT02237261Phase 2
- A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)TerminatedNCT02235740Phase 1
- A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple MyelomaWithdrawnNCT02230917Phase 2
- Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple MyelomaCompletedNCT02221479Phase 2
- Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple MyelomaCompletedNCT02220608Phase 1
- Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02219178Phase 2
- Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple MyelomaCompletedNCT02217163Phase 2